entertainment -WSS

entertainment

author：explore 2025-10-01 01:00:16 - browse：4688

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How to make AI work for medicine

leisure time

WSS

With psoriasis trial ahead, Alumis raises $259 million

With psoriasis trial ahead, Alumis raises $259 million

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

As pharma fights Medicare drug negotiation, hospitals, docs silent

Neuroscience startup Neumora files for IPO

Departing Stanford president retracts two papers

knowledge

entertainment

leisure time

The high cost of giving birth even with insurance

2024 GOP presidential candidates spar over abortion in debate

Novavax promises a turnaround & Lilly roils the obesity market

IVF, abortion rights issues kick off Biden’s State of the Union

Cancer drug shortages should be causing more outrage

In science, is the line between industry and academia shifting?

23andMe had bad news about my health. I wish a person had delivered it

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Wildfire smoke exposes gaps in outdoor worker protections

How to make Best Hospitals ratings actually useful for patients

hotspot

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

With psoriasis trial ahead, Alumis raises $259 million

Diversity in medical illustrations gets boost from Chidiebere Ibe

What it’s like to watch children die of measles

AstraZeneca challenges Medicare drug negotiation program

NYU Langone launches private ChatGPT for its health care data

hotspot

leisure time

focus

Wikipedia